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Abstract
The DNA double-strand break (DSB) is the primary lethal lesion after therapeutic radiation. Thus,
the development of assays to detect and to quantitate these lesions could have broad preclinical
and clinical impact. Phosphorylation of histone H2AX to form γ-H2AX is a known marker for
irradiation-induced DNA DSBs. However, the first generation assay involves the use of
immunofluorescent staining of γ-H2AX foci. This assay is time consuming, operator dependent and
is not scalable for high throughput assay development. Thus, we sought to develop a new assay
using a high throughput electrochemiluminescent platform from Mesoscale Discovery Systems to
quantify γ-H2AX levels. The results show that our assay utilizes significantly less time and labor, has
greater intra-assay reproducibility and has a greater dynamic range of γ-H2AX versus irradiation
dose.
Introduction
Because the DSB is the critical lesion induced by ionizing
radiation in terms of cell killing, their analysis provides
essential insight into fundamental and translational radi-
obiology. However, DSBs are relatively infrequent as com-
pared to the other radiation-induced lesions such as SSB
and base damage, resulting in technical challenges in the
development of specific analytical procedures. Standard
techniques for quantifying DSB induction and repair have
included pulsed field gel electrophoresis (PFGE) and the
neutral comet assay [1]. Over the last several years, γ-
H2AX expression has been established as a sensitive indi-
cator of DSBs [2]. At sites of radiation-induced DNA DSBs,
the histone H2AX becomes rapidly phosphorylated (the
phosphorylated form is referred to as γ-H2AX) forming
readily visible nuclear foci [2,3]. Although the specific role
of γ-H2AX in the repair of DSBs has not been defined,
recent reports indicate that the dephosphoryation of γ-
H2AX and dispersal of γ-H2AX foci in irradiated cells cor-
relates with the repair of DNA DSBs [4-6]. Moreover,
Macphail et al in their study of ten cell lines reported that
the loss of γ-H2AX correlates with clonogenic survival
after irradiation [7].
Currently, immunofluorescent staining is one method for
evaluation of γ-H2AX [8]. However, the assay typically
involves the manual counting of nuclear foci, with each
focus containing γ-H2AX molecules. The assay also has a
limited dose range and is not amenable to high through-
put screening (HTS). γ-H2AX may also be evaluated by
immunoblot assay but this technique is time and labor
intensive, has a fairly narrow range of detection, and also
is not scalable to HTS. Lastly, flow cytometry has been
used to analyze γ-H2AX; however, flow cytometry meth-
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the aforementioned methods of evaluating γ-H2AX is
effective and has provided important information, there is
still a need for an analytical high throughput assay that is
capable of screening radiomodifying drugs across diverse
cell lines and in vivo tissue. We show that using an electro-
chemiluminescent detection system, γ-H2AX can be eval-
uated in both cultured cell lines and in vivo murine tissue
with an efficient, reproducible methodology that is scala-
ble for HTS [9].
Materials and methods
Cell lines and treatment
The human glioblastoma cell line (U251) and pancreatic
cell line (MiaPaca) were obtained from the National Can-
cer Institute Frederick Tumor Repository. The breast
tumor cell line variant MDA-MB-231BR was supplied by
the laboratory of Patricia Steeg (National Cancer Institute,
Bethesda, MD). Cells were grown in DMEM (Invitrogen)
with glutamate (5 mmol/L) and 10% fetal bovine serum,
and maintained at 37°C, 5% CO2. 17DMAG and perifo-
sine, provided by the Developmental Therapeutics Pro-
gram of the National Cancer Institute, were reconstituted
in DMSO (100 mmol/L) and PBS (100 mmol/L) respec-
tively, and stored at -20°C. Cells were irradiated using a
Pantak X-ray source at a dose rate of 2.28 Gy/min.
Clonogenic assays
Cultures were trypsinized to generate a single cell suspen-
sion and a specified number of cells was seeded into each
well of a six-well tissue culture plate. After allowing cells
time to attach (4 h), cultures received 17DMAG (50 nmol/
L) and perifosine (9 μmol/L) or DMSO (vehicle control)
for 16 h before irradiation: media was then removed and
replaced with drug-free media. Ten to fourteen days after
seeding, colonies were stained with crystal violet, the
number of colonies containing at least 50 cells was deter-
mined, and surviving fractions were calculated.
Immunofluorescent staining for γ-H2AX
Immunofluorescent staining and counting of γ-H2AX
nuclear foci was performed as previously described [9].
Slides were examined on a Leica DMRXA fluorescent
microscope. Images were captured by a Photometrics Sen-
γ-H2AX evaluation post-irradiationFigure 1
γ-H2AX evaluation post-irradiation. (A) U251 cells were plated onto chamber slides, irradiated at the specific doses, and 
fixed for immunocytochemical analysis. Foci were evaluated three times in 30 nuclei per treatment per experiment. (B) Plot of 
the linear dynamic range of the immunofluorescent staining assay. (C) Plot of the linear dynamic range of the MSD Assay.Page 2 of 5
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Labs image analysis software package (Scanalytics, Inc.).
For each treatment condition, γ-H2AX foci were deter-
mined in at least 50 cells. Cells were classified as positive
(i.e., containing radiation-induced γ-H2AX foci) when
more than five foci were detected.
MSD Direct Coat Assay
Cells were grown and treated on 100 mm plates. After
specified treatments and incubations, cells were har-
vested: scraped into PBS, washed, and frozen overnight at
-80°C. Each cultured condition was resuspended in lysis
buffer containing NaCL (500 mM), EDTA (2 mM), Triton
X-100 (1%), sodium deoxycholate (1%), SDS (1%), Tris
HCl (50 mM), NaF (10 mM), phosphatase and protease
inhibitors (1×), and PMSF (2 mM). Proteins were solubi-
lized by sonication, concentrations determined by Brad-
ford assay, and lysates coated onto MSD high bind plates.
Wells were blocked with 3% blocking solution, washed,
and a sulfo-ester tag conjugated phospho-H2AX (Abcam)
detection antibody was added in 1% blocking solution (1
μg/ml). Wells were washed 3× and 1× MSD Read Buffer
was added before analysis in a MSD Sector Imager 2400.
Animal Methods
All animal studies were conducted in accordance with the
principles and procedures outlined in the NIH Guide for
the Care and Use of Animals. Four to six week old nude
mice were injected subcutaneously with U251 cells (1 ×
106) on the lateral aspect of the rear leg. When tumors
reached 500 mm3 mice were irradiated. Mice were sacri-
ficed, tumors extracted, tissue homogenized, and resus-
pended in lysis buffer. The MSD Assay was carried out as
stated above.
Statistical analysis
In vitro experiments were repeated thrice and statistical
analysis was done using a Student's t test. Data are pre-
sented as mean ± SD. A probability level of a P value of <
0.05 was considered significant.
Results and Discussion
A critical determinant of radiation-induced cytotoxicity is
the induction and repair of DNA damage, specifically
DSBs [10]. The two main confounders to the current γ-
H2AX foci assay are the manual quantitation and the lim-
ited range of the assay. To demonstrate the more limited
dose range, immunofluorescent staining was performed
on U251 cells 1 hour post irradiation at doses from 08 Gy
(Figure 1). This figure and all that follow is a representa-
tive figure from one of three independent experiments. As
shown, exposures higher than 4 Gy result in foci satura-
tion, reducing the useful range of the assay to doses less
than 4 Gy. As a measure of linearity, we calculated the R
squared value for figure 1B as 0.815. Comparatively, as
shown in figure 1C, the γ-H2AX MSD assay (96-well for-
mat) has a linear dynamic range up to 8 Gy (R squared
value is 0.967) with a high intra-assay reproducibility.
Though manual foci counting may be more sensitive than
the MSD assay (larger difference in values between unirra-
diated and 2 Gy), the MSD assay data reflect a greater lin-
ear dynamic range. To determine whether the results
derived from the MSD system were broadly applicable,
additional cell lines (MDA-MB-231BR and MiaPaca) were
irradiated and assayed for γ-H2AX at varied doses of IR.
Reproducible γ-H2AX levels that were dose dependent
were derived for the two additional cell lines (data not
shown). In addition to measuring the initial number of
DNA DSBs produced after irradiation, the kinetics of the
Comparison of foci versus MSD for the evaluation of DNA-DSB repairFigure 2
Comparison of foci versus MSD for the evaluation of DNA-DSB repair. The U251 cell line was plated out onto cham-
ber slides for the immunofluorescent assay in which foci counting was utilized. U251 cells were plated onto 100 mm plates for 
the MSD assay. Irradiation was carried out and the respective assays were performed at designated time points.Page 3 of 5
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(Figure 2), the repair kinetics for U251 were similar when
measured using either the standard immunofluorescent
foci assay or the MSD assay. Thus, the MSD assay can be
used across a diversity of cell lines to measure the kinetics
of γ-H2AX accumulation and dispersal.
We have previously published that Hsp90 inhibition
enhances tumor cell killing as measured by clonogenic
survival, the gold standard for radiation sensitizer devel-
opment [11]. To demonstrate the potential of the MSD
platform to screen drugs as radiation sensitizers, we used
this new assay to evaluate the known radiosensitizer 17
DMAG [12]. To determine the effects of the Hsp90 inhib-
iting drug 17 DMAG on GBM tumor cell radiosensitivity,
clonogenic survival analysis was first performed on the
U251 cell line. 16 h after 17 DMAG (50 nM) addition,
U251 cells were irradiated followed by a change to drug-
free media with colony-forming efficiency determined 10
days later. As shown in Figure 3A, this 17 DMAG pretreat-
ment increased U251 radiosensitivity with a dose
enhancement factor at a surviving fraction of 0.10 to 1.60,
consistent with previous results. In subsequent experi-
ments, U251 cells were exposed to 50 nmol/L of 17
DMAG for 16 hours, irradiated, fed fresh media, and har-
vested at specific time points. The MSD assay showed
retention of γ-H2AX at 24 h post-irradiation in the irradi-
ated cells that were treated with 17 DMAG, which is con-
sistent with non-repair of DNA-DSBs and, thus, a
radiosensitizing effect on the GBM tumor cell line match-
ing the clonogenic survival assay (Figure 3B). In addition
to the drug 17 DMAG, as a negative control, we investi-
The effect of drugs on tumor cell radiosensitivityFigure 3
The effect of drugs on tumor cell radiosensitivity. (A) U251 Cells were seeded as a single-cell suspension and with a 
specified number of cells. After allowing cells time to attach (4 h), 17 DMAG or the vehicle control was added (50 nmol/L) and 
the plates were irradiated 16 h later. Ten to twelve days after seeding, survival curves were generated after normalizing for the 
cytotoxicity generated by 17 DMAG alone. Data presented are the mean ± SE from at least three independent experiments. 
(B) Identical experimental conditions as (A) followed by the MSD assay. (C) The non-radiosensitizing effect of perifosine car-
ried out by the MSD assay. U251 cells were treated with perifosine (9 μmol/L) alone and the combination of perifosine and IR.Page 4 of 5
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modifying effect. Previous studies using clonogenic
survival assays have shown perifosine does not have an
effect on repair of DNA-DSBs [13]. Using the MSD assay,
we show no increase of γ-H2AX in the combination group
compared to the irradiation alone group at 24 h, consist-
ent with the previously published clonogenic assays (Fig-
ure 3C).
Finally, the γ-H2AX MSD assay was used on protein iso-
lates from U251 tumors grown subcutaneously in SCID
mice, irradiated at 10 Gy and harvested 1 hour post IR. As
shown in Figure 4, although there is intra-mouse variabil-
ity, there is also an increase in γ-H2AX after irradiation
demonstrating that the γ-H2AX MSD assay works not only
with in vitro samples but in vivo samples as well. Thus, the
γ-H2AX MSD assay can be used as an adjunct to other pre-
clinical assays in evaluating drugs as radiation sensitizers.
Because γ-H2AX expression is an indicator of DSB induc-
tion and repair, the development of an analytical method
adaptable to a high throughout approach would appear to
have a number of applications related to drug develop-
ment for either radiation sensitizers or for other drugs that
kill tumor cells via induction of DNA DSBs. Towards this
end, we have demonstrated that the γ-H2AX MSD assay
has excellent reproducibility, is quantitative, and applica-
ble to multiple cell types from either in vitro or in vivo sam-
ples. We have also shown that the MSD assay may allow
the more rapid development of radiomodifying drugs in a
high throughput fashion.
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Evaluation of γ-H2AX In VivoFig re 4
Evaluation of γ-H2AX In Vivo. Tumors were grown in 
mice injected with U251 cells subcutaneously in the flank. 
Mice were irradiated, tissue homogenized, protein isolated 
and the MSD assay was performed.Page 5 of 5
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